Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 10,856 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 61
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more

Conditions: Fibromyalgia, Myofascial Pain Syndrome, Muscular Diseases, Musculoskeletal Disease, Rheumatic Diseases
Interventions: Fibromyalgia Integrative Training for Teens, Cognitive Behavioral Therapy, Graded Aerobic Exercise; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Boston, Massachusetts + 3 more

Conditions: Arthroplasty, Replacement, Shoulder
Interventions: Regeneten, Standard repair; Device · Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 50 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: Raloxifene, Tamoxifen; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 35 Years and older · Female only
Enrollment: 19,747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 492
States / cities: Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more

Conditions: Pancreatic Neoplasms, Adenocarcinoma
Interventions: Gemcitabine, Etanercept; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Bacterial Vaginoses
Interventions: Metronidazole, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Standard of Care; Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Neoplasms, Prostate
Interventions: Dutasteride, Matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 58
States / cities: Little Rock, Arkansas • Beverly Hills, California • Laguna Hills, California + 54 more

Conditions: Osteoarthritis of the Knee
Interventions: X0002, Placebo; Drug
Lead sponsor: Lina Xu; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 20
States / cities: Tempe, Arizona • Carmichael, California • Spring Valley, California + 17 more

Conditions: Myopia
Interventions: Atropine Ophthalmic, MiSight 1-day disposable contact lenses; Drug · Device
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years to 30 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: LH-001, Placebo; Drug
Lead sponsor: Chien-Liang Lin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: Test Meal: Reference food (glucose or white bread), Test Meal: Pirate's Booty, Test Meal: Ceaprove wafer, Test Meal: Stretch Island Strawberry Fruit Leather; Drug
Lead sponsor: Glycaemic Index Testing, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Gainsville, Florida • Buffalo, New York • Columbus, Ohio

Conditions: Atopic Dermatitis
Interventions: Upadacitinib (ABT-494); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Huntington Beach, California • Los Angeles, California • Coral Gables, Florida + 12 more

Conditions: Healthy Volunteers
Interventions: Not listed
Lead sponsor: Mark Failla; Other
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: THROMBOLYSIS
Interventions: Tenecteplase, Placebo; Biological · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 94
States / cities: Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more

Conditions: High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions: Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 40 Years
Enrollment: 1,122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 181
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more

Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions: Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 258
States / cities: Phoenix, Arizona • Tucson, Arizona • Dublin, California + 209 more

Conditions: Dyslipidemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 27,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 326
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide Once Weekly, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 14,752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 139
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more

Conditions: Cancer of the Breast, Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Male Breast Cancer, Triple Negative Breast Cancer, ER+ Breast Cancer
Interventions: Seviteronel; Drug
Lead sponsor: Innocrin Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Huntsville, Alabama • Aurora, Colorado + 30 more

Conditions: Glioblastoma Multiforme
Interventions: TPI 287, Bevacizumab; Drug
Lead sponsor: Cortice Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • St Louis, Missouri • Hackensack, New Jersey + 6 more

Conditions: Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
Interventions: Seclidemstat, Cyclophosphamide, Topotecan; Drug
Lead sponsor: Salarius Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 16
States / cities: Los Angeles, California • Santa Monica, California • Jacksonville, Florida + 13 more

Conditions: Hepatocellular Carcinoma, HCC
Interventions: Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin; Radiation · Procedure · Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Burlington, Massachusetts • Rochester, Minnesota • Omaha, Nebraska + 1 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine 56 mg, Esketamine 84 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 54
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more

Search by objective public record fields.

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia

Evaluation of Regeneten Augmentation for Subscapularis Healing After Total Shoulder Arthroplasty (RESTOR)

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis

Changes in Eye Shape With Myopia Management Interventions

LH-001 vs Placebo in Healthy Participants

GI Interlab 2 Study: Measuring the Glycaemic Index (GI) of Foods

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Bioavailability of Xanthones From Mangosteen

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression